BIOSTAT® RM TX and Flexsafe® RM TX Bags
14 February 2019 | By Sartorius
The BIOSTAT® RM TX system consists of an automated control unit and a rocking platform, for gently agitating a single-use Flexsafe® RM bag...
List view / Grid view
14 February 2019 | By Sartorius
The BIOSTAT® RM TX system consists of an automated control unit and a rocking platform, for gently agitating a single-use Flexsafe® RM bag...
17 January 2019 | By IntelliCyt, a Sartorius Company
Multiplexed approach to measure T-cell activation, proliferation and quantify cytokine release in a single well
Controlling coronin 1 in T-cells could lead to the immune system not attacking transplanted organs, but still fighting other infections...
Researchers have identified an innovative and promising therapeutic option to treat multiple sclerosis...
Phospholipid-reactive T-cells that are able to recognise phospholipids could help in treatments against cancer, autoimmune diseases and dyslipidemia...
Researchers have genetically engineered immune cells to recognise and fight Hodgkin and non-Hodgkin lymphoma cells...
War On Cancer 2018 discussed how cancer treatments have evolved over the last few decades, and looked at the future of cancer therapies...
RIP1 has been shown to suppress the action of macrophages against the immune system and could be a potential therapeutic target for pancreatic cancer...
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...
Genetic barcoding using Pro-codes and CRISPR could be used to identify critical cancer immunity genes to aid future therapeutics...
Using sugar molecules researchers have developed a new vaccine for hay fever that may reduce treatment times and increase the effectiveness of treatments...
Cancer cells have been found to evade immunotherapy by hiding behind human leukocyte antigens, with researchers identifying therapies to prevent relapse...
Researchers in the U.S. have made a surprising discovery about the binding behaviour of a particular T-cell receptor, with complicated ramifications for immunotherapy developers.
An integrated fragment-based approach, which reveals enzymatic inhibitors with potential therapeutic application, is the subject of this webinar.Taking place on 25 October 2018 at 3:00pm, the webinar is supported by NanoTemper Technologies.
Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anti-cancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy and bispecific T-cell engagers. While these approaches use different tactics to attack tumours, they often employ monoclonal antibodies to target…